- Home
- MCR vs ANNX Comparison
MCR vs ANNX Comparison
Compare MCR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- ANNX
- Stock Information
- Founded
- MCR 1989
- ANNX 2011
- Country
- MCR United States
- ANNX United States
- Employees
- MCR N/A
- ANNX N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- ANNX Health Care
- Exchange
- MCR Nasdaq
- ANNX Nasdaq
- Market Cap
- MCR 250.1M
- ANNX 252.3M
- IPO Year
- MCR N/A
- ANNX 2020
- Fundamental
- Price
- MCR $6.29
- ANNX $2.38
- Analyst Decision
- MCR
- ANNX Strong Buy
- Analyst Count
- MCR 0
- ANNX 4
- Target Price
- MCR N/A
- ANNX $12.50
- AVG Volume (30 Days)
- MCR 66.7K
- ANNX 1.4M
- Earning Date
- MCR 01-01-0001
- ANNX 08-11-2025
- Dividend Yield
- MCR 8.52%
- ANNX N/A
- EPS Growth
- MCR N/A
- ANNX N/A
- EPS
- MCR 0.38
- ANNX N/A
- Revenue
- MCR N/A
- ANNX N/A
- Revenue This Year
- MCR N/A
- ANNX N/A
- Revenue Next Year
- MCR N/A
- ANNX N/A
- P/E Ratio
- MCR $16.61
- ANNX N/A
- Revenue Growth
- MCR N/A
- ANNX N/A
- 52 Week Low
- MCR $5.63
- ANNX $1.29
- 52 Week High
- MCR $6.70
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- MCR 53.00
- ANNX 54.50
- Support Level
- MCR $6.22
- ANNX $2.25
- Resistance Level
- MCR $6.31
- ANNX $2.49
- Average True Range (ATR)
- MCR 0.04
- ANNX 0.19
- MACD
- MCR -0.01
- ANNX -0.03
- Stochastic Oscillator
- MCR 53.57
- ANNX 26.32
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.